Clinical trials: Lipemia
Hypercholesterolemia
Investigating Effects of a Novel Nutraceutical on Hypercholesterolaemia in Australian Adults
To evaluate the effects of daily consumption of 3 capsules of Swisse Nutra+ Cholesterol Balance on serum LDL-cholesterol in adults with hypercholesterolaemia compared to placebo over four months.
- Trial name
- CLoNE (NCT04783714)
- Testing
- Swisse Nutra+ Cholesterol Balance
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Swisse Wellness Pty Ltd
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin therapy with or without other lipid modifying therapy in comparison with…
- Trial name
- NCT02107898
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 32 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Sanofi
Hypercholesterolemia, Dyslipidemias
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
- Trial name
- PIVOTAL (NCT07083206)
- Where
- South Korea
- Volunteers
- 4,500 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Hypertriglyceridemia, Metabolic Syndrome
Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
This study is a prospective observational program within the frames of which Tricor (fenofibrate) is prescribed to patients with hypertriglyceridemia within a routine procedure as a part of the combination therapy with statins.
- Trial name
- TRISTAN (NCT04650152)
- Testing
- Tricor (fenofibrate), 145 mg, film-coated tablet
- Where
- 63 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- Abbott
Hypercholesterolemia
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic
This study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of DC739 after multiple-dose oral administration, to explore the clinical effective dose, and to initially explore the efficacy and safety in…
- Trial name
- NCT04927221
- Testing
- DC371739 Tablets
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
High Blood Cholesterol
An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon
This was a multicenter survey of patients who were on lipid -lowering pharmacological treatment in 2 Levant countries namely Jordan and Lebanon.
- Trial name
- CEPHEUS (NCT01614561)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Hyperlipidemias
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol…
- Trial name
- NCT03337308
- Testing
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe
- Where
- 5 sites in United States
- Volunteers
- 382 people
- Sponsor
- Esperion Therapeutics, Inc.
Hypercholesterolaemia
Dose Effect of Limicol on (LDL)-Cholesterol Levels
The principal objective of this study is to investigate the dose-effect of the Limicol food supplement on LDL-cholesterol level in moderate hypercholesterolaemia subjects.
- Trial name
- NCT01354340
- Testing
- Limicol
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Lescuyer Laboratory
Type 2 Diabetes Mellitus, Cardiovascular Disease
Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease
The purpose of this study is to evaluate the Efficacy and Safety of Dehypotin® in the Patients with Type 2 Diabetes Mellitus or Cardiovascular Disease.
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- NCT01108978
- Testing
- Dehypotin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
Primary Hypercholesterolaemia
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance.
- Trial name
- NCT00396240
- Testing
- Rosuvastatin, Initiatives to improve compliance
- Volunteers
- 1,294 people
- Sponsor
- AstraZeneca
Hypercholesterolaemia
Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets
Single dose oral bioequivalence study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets in healthy adult human subjects under fasting conditions.
- Trial name
- NCT07170852
- Testing
- Bempedoic acid film coated tablet, Nilemdo® Film-coated tablets
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Hypercholesterolemia
Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R…
- Trial name
- NCT04289285
- Testing
- IBI306 450mg SC Q4W, IBI306 600mg SC Q6W
- Where
- China
- Volunteers
- 804 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Participants, Hyperlipidemia
A Phase 1 Study of VELA-101 in Adult Participants
This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses…
- Trial name
- NCT07864311
- Testing
- VELA-101
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ursa Medicines
Hypercholesterolemia
Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)
The primary outcome was percentage reduction of LDL-C after 6 weeks of randomization.
- Trial name
- NCT00652444
- Testing
- ezetimibe, simvastatin
- Volunteers
- 120 people
- Sponsor
- Organon and Co
Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.
- Conditions
- Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
- Trial name
- NCT03360747
- Testing
- AKCEA-ANGPTL3-LRx
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Akcea Therapeutics
Hyperlipidemias
Effect of ANKASCIN 568-P Products Regulating Blood Lipid
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Trial name
- NCT05737355
- Testing
- ANKASCIN 568-P Red yeast rice capsules
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- SunWay Biotech Co., LTD.
Hypercholesterolemia
Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia
A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy of a red yeast rice based nutraceutical (monacolin K 10 mg/dose) plus probiotic (Bifidobacterium longum BB536 ®), versus placebo, in patients…
- Trial name
- NCT02689934
- Testing
- Lactoflorene colesterolo
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Montefarmaco OTC SpA
Hypercholesterolemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.
AZD8233 has not been evaluated in clinical studies previously. This is a first-in-human (FiH) study. This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD8233, following subcutaneous (SC) administration…
- Trial name
- NCT03593785
- Testing
- AZD8233
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.